Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces Publication of Research Report by Grass Roots Research and Distribution, Inc.
May 12, 2010

Nutra Pharma has announced that Grass Roots Research and Distribution, Inc. has published a research report updating coverage of Nutra Pharma.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Grass Roots Research and Distribution, Inc. has published a research report updating coverage of Nutra Pharma Corporation.

The publication from Grass Roots Research and Distribution, Inc., which was commissioned by Nutra Pharma, focuses on the company’s current drug development initiatives, including the company’s leading drug candidates for the treatment of Multiple Sclerosis (MS), HIV, Adrenomyeloneuropathy (AMN), and Rheumatoid Arthritis (RA) as well as the company’s recent launch of Cobroxin and Nyloxin, treatments for chronic pain.

A PDF of the research report can be accessed at: http://www.grassrootsrd.com/grassrootsrd/Reports/Nutra_Pharma_Corp_05_12_2010.pdf

About Grass Roots Research and Distribution, Inc.

The Grass Roots Research and Cohen Research brand names are the worldwide Gold Standard for micro cap/small cap research. Grass Roots has raised the art of fundamental securities research by forecasting the three statements and valuing all of its companies in three cases over a 5 year time period. Grass Roots distributes in-depth stock market research reports that highlight the company's market opportunity, technology, management, competition and other key differentiators that may affect their short and long term valuation.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC").   Announcing the publication of the research report by Grass Roots Research and Distribution, Inc. should not be construed as an indication in any way whatsoever of the value of the Company or its common stock.  The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
March 14, 2017
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


February 22, 2017
Global Small Caps Initiates Coverage on Nutra Pharma


February 15, 2017
Nutra Pharma and Nyloxin Featured on NBC News-Miami


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics